BriaCell Therapeutics Corp Warrant
BCTXW
BCTXW was delisted on the 26th of February, 2026.
6 hedge funds and large institutions have $1.19M invested in BriaCell Therapeutics Corp Warrant in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
144.15% more ownership
Funds ownership: 0% → 144.15% (+144%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$489K |
| 2 |
AC
Armistice Capital
New York
|
+$412K |
| 3 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
+$73.4K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$58.1K |
| 5 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$44.1K |
Top Sellers
BCTXW Hedge Fund Activity: Q1 2021 in Review
6 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q1 2021, worth a combined $1.19M.
Buyers outnumbered sellers: 6 funds opened new BCTXW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $489K.
- 6 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.19M of BriaCell Therapeutics Corp Warrant stock for Q1 2021.
- 6 funds opened new BriaCell Therapeutics Corp Warrant positions in Q1 2021 and 0 closed out, a net change of +6 holders.
- The largest BriaCell Therapeutics Corp Warrant buyer in Q1 2021 was Altium Capital Management, an estimated $489K added.
Based on aggregated 13F filings for Q1 2021.